Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. (Nasdaq: ALT) is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapeutics and vaccines addressing critical public health and biodefense needs. Leveraging the unique properties of its proprietary platform technologies, Altimmune is adept at swiftly designing product candidates targeting a range of diseases, including respiratory conditions, chronic infections, and cancer.
Altimmune's advanced Densigen™ T-cell platform technology is specifically designed to guide the immune system's response against complex disease targets by focusing on multiple antigens simultaneously. Another key platform, RespirVec™, uses needle-free intranasal delivery for faster and broader immunity against pathogens compared to traditional vaccines.
The company is also heavily involved in addressing obesity and liver diseases through its innovative peptide therapeutics. The lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist under development for obesity and non-alcoholic steatohepatitis (NASH). Pemvidutide has shown promising results in clinical trials, achieving significant weight loss and liver fat reduction. It has received Fast Track designation from the U.S. FDA for treating NASH, highlighting its potential to meet significant unmet medical needs.
Altimmune's pipeline also includes HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. However, the company has recently decided to cease further development on HepTcell based on Phase 2 trial findings.
Financially, Altimmune maintains a robust cash position, enabling it to advance its clinical programs. Recent financial results indicate a focused investment in research and development, ensuring continued progress in its pipeline.
Significant recent achievements include:
- Positive top-line results from the 48-week MOMENTUM Phase 2 obesity trial of pemvidutide.
- Ongoing Phase 2b IMPACT trial of pemvidutide in MASH with top-line results expected in Q1 2025.
- Strong financial position with substantial cash reserves to support ongoing and future research activities.
Altimmune is poised at the forefront of developing transformative therapies for serious health conditions, potentially delivering significant advancements in patient care.
Altimmune, a clinical-stage biopharmaceutical company, has received FDA clearance for its IND application for the pemvidutide Phase 2 clinical trial targeting obesity. The trial is set to begin in Q1 2022, enrolling around 320 participants. Pemvidutide aims to treat obesity and has previously shown promising results, with a 10.3% average weight loss in a Phase 1 study. This trial will evaluate multiple dosages over 48 weeks, focusing on weight change and metabolic health. The company also develops treatments for non-alcoholic steatohepatitis (NASH).
Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Scott Harris, Chief Medical Officer, will present on pemvidutide, a dual receptor agonist targeting obesity and non-alcoholic steatohepatitis (NASH). The presentations will occur at the NASH-TAG Conference from January 6-8, 2022, in Park City, Utah. Dr. Harris will deliver an oral presentation on a placebo-controlled study of pemvidutide on January 8, 2022, at 8:10 am Mountain Time. The presentation details will be available on Altimmune's website post-conference, emphasizing the company's focus on innovative treatments for obesity and liver diseases.
Altimmune, Inc. (Nasdaq: ALT) announced the recruitment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021. The Compensation Committee granted him equity awards under its 2018 Inducement Grant Plan, which includes options for 150,000 shares and 50,000 restricted stock units (RSUs). The exercise price for options will match the stock's closing price on the Grant Date. Vesting for these awards is contingent upon Mr. Eisenstadt’s continued employment, with full vesting occurring over four years.
Altimmune, Inc. (Nasdaq: ALT) announced the appointment of Richard Eisenstadt as Chief Financial Officer effective December 31, 2021, succeeding Will Brown. Eisenstadt brings over 30 years of experience in healthcare, demonstrating his capacity for managing drug development and commercial operations. He previously served as CFO at Aytu BioPharma and Neos Therapeutics, where he raised over $340 million. The leadership change comes as Altimmune aims to advance its clinical pipeline, including pemvidutide for obesity and HepTcell for chronic hepatitis B.
Altimmune, Inc. (Nasdaq: ALT) announced its management team's participation in several upcoming virtual conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference will take place from November 29 to December 2, 2021. The 5th Annual NASH Summit 2021 is scheduled for November 30, 2021, at 9:00 am Eastern Time. Lastly, Altimmune will present at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021, at 10:55 am Eastern Time. Presentation materials and webcasts are accessible on their website.
On November 10, 2021, Altimmune, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker ALT, announced upcoming presentations by its management team at two significant investor conferences.
- Stifel’s 2021 Virtual Healthcare Conference: November 15, 2021, at 10:40 am Eastern Time.
- Jefferies London Healthcare Conference: November 18, 2021, at 8:00 am GMT.
Both sessions will be accessible via the Altimmune website.
Altimmune, Inc. (Nasdaq: ALT) reported significant advancements in its pemvidutide program, showcasing a reduction of liver fat to undetectable levels in subjects with hepatic steatosis following a 6-week treatment. The company ended Q3 2021 with approximately $200 million in cash and short-term investments.
Financially, Altimmune's Q3 revenue was $0.2 million, down from $2.9 million in Q3 2020, with a net loss of $33.5 million. The firm is advancing its obesity program and is set to initiate Phase 2 trials in 2022.
Altimmune, Inc. (Nasdaq: ALT) has announced that it will report its third quarter 2021 financial results on November 10, 2021. The management team will host a conference call at 8:30 am E.T. to discuss these results and provide a business update. Investors can participate via domestic and international dial-in numbers or join a webcast available through their official site.
Altimmune focuses on developing treatments for obesity and liver diseases, with ongoing projects like ALT-801 for NASH and HepTcell™ for chronic hepatitis B.
Altimmune, a clinical-stage biopharmaceutical company, has announced that its management will present virtually at two upcoming H.C. Wainwright Investor Conferences. The presentations include the 5th Annual NASH Investor Conference on October 12, 2021 at 3:30 PM ET, and the Hepatitis B Virus Virtual Conference on October 13, 2021 at 4:30 PM ET. Interested individuals can access the sessions via the Events section on Altimmune's website.
Altimmune focuses on developing treatments for obesity and liver diseases, with key products including next-generation peptide therapeutics.
Altimmune has announced the enrollment of the first patient in a 12-week Phase 1b clinical trial for pemvidutide aimed at treating non-alcoholic fatty liver disease (NAFLD). Led by Dr. Stephen Harrison, the trial aims to include approximately 72 patients and is expected to read out topline data in the first half of 2022. Pemvidutide, a dual receptor agonist, has shown promising results in weight loss and metabolic health, with plans to initiate a Phase 2 NASH study based on the findings from this trial.
FAQ
What is the current stock price of Altimmune (ALT)?
What is the market cap of Altimmune (ALT)?
What does Altimmune, Inc. specialize in?
What are the main products in Altimmune's pipeline?
What is pemvidutide?
Has pemvidutide received any regulatory designations?
What is Densigen™ platform technology?
How does the RespirVec™ platform work?
What recent financial results has Altimmune reported?
What are the current clinical trials for pemvidutide?
What is the status of HepTcell™ development?
Where can I find more information about Altimmune?
